Another possible reason that the therapeutic effects of doxorubicin are limited because the excretion of doxorubicin in cancer cells is driven by efflux transporters (e.g., P-glycoprotein and breast cancer resistance protein), resulting in rapid growth of these surviving cancer cells after drug withdrawal. The gene discussed is ABCB1; the disease is cancer.